12:00 AM
Dec 10, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Avagacestat: Development discontinued

Bristol-Myers discontinued development of avagacestat after data from a pair of Phase II trials in patients with mild to moderate AD and predementia AD, respectively, did not "establish a profile that supported advancement" to Phase III testing. The pharma plans to present...

Read the full 190 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >